

Cat No. 55-X21

Everolimus


10mg

Everolimus inhibits mTOR (mammalian target of rapamycin), a serine-threonine kinase, by binding with high affinity to the FK506 binding protein-12 (FKBP-12) thus inducing cell growth arrest and apoptosis. It is chemically very similar to Rapamycin. It is also used to prevent rejection of organ transplants.



For research purposes only

TECHNICAL INFORMATION



Other Names: 40-O-(2-Hydroxyethylrapamycin)

Chemical Formula: C₅₃H₈₃N₁₄

CAS Number: 159351-69-6

PubChem Substance ID: 46930999

Molecular Weight: 958.22

Purity: >99%

Appearance: Off white crystalline solid

Solubility: DMSO

IC₅₀ : .63nM

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in DMSO. Soluble at 20mg/ml.

REFERENCES

1. Motzer, R.J., et al (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. *Lancet*. 372:449-56.
2. Baselga, J., et al (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med*. 366:520-9.
3. Yao, J.C., et al (2011). Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med*. 364:514-23.

STORAGE AND HANDLING